Press Releases

Press Releases

    Date Title View
    04/02/20
    Summary ToggleHorizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
    03/31/20
    Summary ToggleTEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
    PDF Version
    03/26/20
    Summary ToggleHorizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
    PDF Version
    03/03/20
    Summary ToggleHorizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
    PDF Version
    02/28/20
    Summary ToggleHorizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
    PDF Version
    02/28/20
    Summary ToggleHorizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
    PDF Version
    02/27/20
    Summary ToggleHorizon Therapeutics plc Named One of the Best Workplaces in Ireland
    PDF Version
    02/26/20
    Summary ToggleHorizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
    02/18/20
    Summary ToggleHorizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
    PDF Version
    02/18/20
    Summary ToggleHorizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
    PDF Version
    Displaying 1 - 10 of 18 results